Oncology Central

The impact of dendritic cell–tumor fusion cells on cancer vaccines – past progress and future strategies

0

Dendritic cells (DCs) are potent antigen-presenting cells that can be used in cancer vaccines. Thus, various strategies have been developed to deliver tumor-associated antigens via DCs. One strategy includes administering DC–tumor fusion cells (DC–tumor FCs) to induce antitumor immune responses in cancer patients. However, clinical trials using this strategy have fallen short of expectations. Several factors might limit the efficacy of these anticancer vaccines.

To view restricted content, please:
Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.